REVISITING THE ORIGINS OF COMPULSORY DRUG PRESCRIPTIONS

被引:34
作者
MARKS, HM
机构
关键词
D O I
10.2105/AJPH.85.1.109
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
It has been argued that today's prescription drug market originated in the arbitrary acts of the US Food and Drug Administration (FDA), which in 1938 issued regulations creating a class of drugs that could be sold by prescription only. On the basis of the FDA's administrative records, I argue that the 1938 regulations on prescription drug labeling were initiated by industry and then agreed to by the FDA; that contemporaries understood and accepted the reasons for restricting the use of certain drugs; and that the subsequent evolution of these regulations is best understood as an FDA effort to limit industry abuses of the prescription labeling system. This decade-long war of position ended when drug manufacturers persuaded the US Congress to enshrine their version of prescription labeling in law in a highly politicized struggle over government's role in the economy.
引用
收藏
页码:109 / 115
页数:7
相关论文
共 101 条
[31]  
*FED SEC ADM, 1950, ANN REP, P214
[32]  
FISHBEIN, 1937, COMMUNICATION 0127
[33]  
*FOOD DRUG ADM, 1949, ANN REP, P25
[34]  
FRAILEY CG, 1949, FOOD DRUG COSMET LAW, V4, P212
[35]  
GRIFFITH R, 1981, TRUMAN PRESIDENCY, P57
[36]  
HARROP LD, 1948, 36TH P ANN M, P27
[37]  
HARROP LD, 1947, 35TH P ANN M, P27
[38]  
HARROP LD, 1949, 37TH P ANN M, P25
[39]   The development of acute hemolytic anemia during the administration of sulfanilamide (Para-aminobenzenesulfonamide) [J].
Harvey, AM ;
Janeway, CA .
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1937, 109 :12-16
[40]  
HARVEY JL, 1950, COMMUNICATION 0714